Internal Medicine, Hematology & Oncology · Fort Lauderdale, FL
NPI
1407180615
Since 2009
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
4725 N Federal Hwy
Fort Lauderdale, FL, 33308
Phone (954) 267-7742
Groups this clinician bills Medicare through
Medicare paid, 2024
$99K
1,245 services
Medicare patients, 2024
529
Average age 77
Drug cost, 2024
$4.4M
1,486 prescriptions
Company payments, 2025
$271
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David Z Drew was code 99214 (office e&m - established), 320 times for 201 patients. In total David Z Drew billed 1,245 services in 19 codes, and Medicare paid $99K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2009-12-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 320 | 201 | $71.18 | $23K |
| 99215 Office E&M - Established | Facility | 272 | 127 | $113.13 | $31K |
| 99213 Office E&M - Established | Facility | 182 | 149 | $49.55 | $9,018 |
| 99232 Hospital E&M - Subsequent | Facility | 84 | 54 | $62.49 | $5,249 |
| 99231 Hospital E&M - Subsequent | Facility | 66 | 42 | $40.08 | $2,645 |
| 99204 Office E&M - New | Facility | 56 | 56 | $103.89 | $5,818 |
| 99222 Hospital E&M - Initial | Facility | 45 | 44 | $103.09 | $4,639 |
| 99203 Office E&M - New | Facility | 44 | 44 | $57.70 | $2,539 |
| 99233 Hospital E&M - Subsequent | Facility | 34 | 23 | $93.70 | $3,186 |
| 99223 Hospital E&M - Initial | Facility | 31 | 31 | $138.38 | $4,290 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 27 | 19 | $25.09 | $678 |
| 99205 Office E&M - New | Facility | 24 | 24 | $139.46 | $3,347 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 11 | 11 | $13.18 | $145 |
By year: 2022 $96K for 1,044 services; 2023 $96K for 1,100 services; 2024 $99K for 1,245 services.
Medicare prescription drug claims, 2024
In 2024, the drug David Z Drew prescribed most often to Medicare patients was Eliquis (Apixaban), with 176 prescriptions and refills. In total David Z Drew wrote 1,486 Medicare prescriptions that cost $4.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 176 | 262 | 45 | $135K |
| Imbruvica Ibrutinib | 85 | 87 | Under 11 | $1.5M |
| Prochlorperazine Maleate Generic | 83 | 83 | 43 | $984 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 72 | 72 | 29 | $833 |
| Prednisone Generic | 64 | 90 | 32 | $335 |
| Abiraterone Acetate Generic | 43 | 43 | Under 11 | $110K |
| Warfarin Sodium Generic | 41 | 98 | Under 11 | $323 |
| Dexamethasone Generic | 40 | 42 | 30 | $887 |
| Alprazolam Generic | 40 | 40 | 13 | $91.96 |
| Xarelto Rivaroxaban | 39 | 92 | 18 | $49K |
| Tagrisso Osimertinib Mesylate | 35 | 35 | Under 11 | $611K |
| Potassium Chloride Generic | 33 | 49 | 13 | $334 |
| Danazol Generic | 31 | 61 | 13 | $10K |
| Ondansetron Odt Ondansetron | 29 | 29 | 15 | $350 |
| Ondansetron Hcl Generic | 29 | 29 | 20 | $235 |
Brand drugs: 505 claims; generic drugs: 981 claims; opioid claims: 115.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David Z Drew $271 ($271 in general payments such as food, travel and fees) from 9 companies. The largest payer was Abbvie Inc. with $120.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.